Biocryst Pharmaceuticals (BCRX) EBIT Margin Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) EBIT Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.47 Bn | 2.12 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,433.00 |
| Mar 31, 2026 | -17,899.00 |
| Dec 31, 2025 | 3.81 Mn |
| Sep 30, 2025 | 72,102.00 |
| Jun 30, 2025 | 135,958.00 |
| Mar 31, 2025 | 86,422.00 |
| Dec 31, 2024 | -315.00 |
| Sep 30, 2024 | 198,392.00 |
| Jun 30, 2024 | 241,948.00 |
| Mar 31, 2024 | 48,260.00 |
| Dec 31, 2023 | 88,000.00 |
| Sep 30, 2023 | 194,589.00 |
| Jun 30, 2023 | 12,098.00 |
| Mar 31, 2023 | 51,739.00 |
| Dec 31, 2022 | 40,093.00 |
| Sep 30, 2022 | 12,938.00 |
| Jun 30, 2022 | 44,769.00 |
| Mar 31, 2022 | 1,316.00 |
| Dec 31, 2021 | -1,949.00 |
| Sep 30, 2021 | 1,028.00 |